Oct 05 2017
Toronto partner Charles Boulakia will be speaking at the AIPPI 2017 World Congress in Sydney.
The time between the invention of an active ingredient (or the second medical use thereof) and the approval of the final drug is significant, often a decade or more. To safeguard rights, patent applications must generally be filed when enough is known to justify further resources, for example, to conduct animal and human studies. Various questions arise in this respect. How can the invention be expressed in a manner sufficient to one of ordinary skill in the art? What experimental or other data are required? Is the invention at issue (e.g. compound or second medical use claim) relevant? How are questions about utility/industrial applicability and obviousness/inventive step resolved? Can post filing data be used to overcome these issues? Variations of these issues arise in many jurisdictions, creating challenges for applicants – in China, over the use of post filing data in overcoming inventive step and sufficiency rejections; in Canada, over the “patent promise” doctrine; and in Europe increasingly over the question of the “plausibility” of the invention as described in the patent specification.
Charles joins other IP experts from Asia, Europe and North America to address these issues in the hope of formulating a global standard.
Date: October 16th (The full AIPPI conference runs October 13-17)
Time: 9:00-1:00 PM
Location: International Convention Centre Sydney (Google Map)
For more information on this conference, please visit the AIPPI World Congress website.
Back to blog overview
Tags: Charles a. Boulakia